Haifeng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haifeng Zhou has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Feixia Shen
Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publications - Guijun Qin
Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Henan, China
2 shared publications - Houfa Geng
Department of Endocrinology, Xuzhou Central Hospital, Xuzhou, China
2 shared publications - Hui Jin
Department of Endocrinology, Zhongda Hospital Southeast University, Nanjing, China
2 shared publications - Hui Liu
Department of Endocrinology, Luoyang Central Hospital, Luoyang, China
2 shared publications - Huiwen Tan
Department of Endocrinology, West China Hospital Sichuan University, Sichuan, China
2 shared publications
Latest Publications
- Open Access
- 26 May 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (8) , 1900-1901
Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
A Correction to this paper has been published: 10.1007/s00125-021-05460-0
- 26 May 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (8) , 1900-1901
Open AccessCorrection to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
A Correction to this paper has been published: 10.1007/s00125-021-05460-0
- Open Access
- 9 March 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (5) , 1066-1078
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
Aims/hypothesis: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) such as exenatide are used as monotherapy and add-on therapy for maintaining glycaemic control in patients with type 2 diabetes mellitus. The current study investigated the safety and efficacy of once-weekly PB-119, a PEGylated exenatide injection, in treatment-naive patients with type 2 diabetes. Methods: In this Phase II, randomised, placebo-controlled, double-blind study, we randomly assigned treatment-naive Chinese patients with type 2 diabetes in a 1:1:1:1 ratio to receive subcutaneous placebo or one of three subcutaneous doses of PB-119 (75, 150, and 200 μg) for 12 weeks. The primary endpoint was the change in HbA1c from baseline to week 12, and other endpoints were fasting plasma glucose, 2 h postprandial glucose (PPG), and proportion of patients with HbA1c < 53 mmol/mol (n = 62 in placebo and 63 each in PB-119 75 μg, 150 μg and 200 μg groups). At the end of 12 weeks, mean differences in HbA1c in the treatment groups were −7.76 mmol/mol (95% CI −9.23, −4.63, p < 0.001) (−0.72%, 95% CI −1.01, −0.43), −12.89 mmol/mol (95% CI −16.05, −9.72, p < 0.001) (−1.18%, 95% CI −1.47, −0.89) and −11.14 mmol/mol (95% CI −14.19, −7.97, p 1c. Similar results were also observed for other efficacy endpoints across different time points. There was no incidence of treatment-emergent serious adverse event, severe hypoglycaemia or death. Conclusions/interpretation: All tested PB-119 doses had superior efficacy compared with placebo and were safe and well tolerated over 12 weeks in treatment-naive Chinese patients with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT03520972 Funding: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio. Graphical
- 9 March 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (5) , 1066-1078
Open AccessEfficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
Aims/hypothesis: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) such as exenatide are used as monotherapy and add-on therapy for maintaining glycaemic control in patients with type 2 diabetes mellitus. The current study investigated the safety and efficacy of once-weekly PB-119, a PEGylated exenatide injection, in treatment-naive patients with type 2 diabetes. Methods: In this Phase II, randomised, placebo-controlled, double-blind study, we randomly assigned treatment-naive Chinese patients with type 2 diabetes in a 1:1:1:1 ratio to receive subcutaneous placebo or one of three subcutaneous doses of PB-119 (75, 150, and 200 μg) for 12 weeks. The primary endpoint was the change in HbA1c from baseline to week 12, and other endpoints were fasting plasma glucose, 2 h postprandial glucose (PPG), and proportion of patients with HbA1c < 53 mmol/mol (n = 62 in placebo and 63 each in PB-119 75 μg, 150 μg and 200 μg groups). At the end of 12 weeks, mean differences in HbA1c in the treatment groups were −7.76 mmol/mol (95% CI −9.23, −4.63, p < 0.001) (−0.72%, 95% CI −1.01, −0.43), −12.89 mmol/mol (95% CI −16.05, −9.72, p < 0.001) (−1.18%, 95% CI −1.47, −0.89) and −11.14 mmol/mol (95% CI −14.19, −7.97, p 1c. Similar results were also observed for other efficacy endpoints across different time points. There was no incidence of treatment-emergent serious adverse event, severe hypoglycaemia or death. Conclusions/interpretation: All tested PB-119 doses had superior efficacy compared with placebo and were safe and well tolerated over 12 weeks in treatment-naive Chinese patients with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT03520972 Funding: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio. Graphical